- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study: Daily aspirin use may reduce risk of ovarian cancer by 20%
- Study: High blood-pressure meds associated with increased injury risk from a fall in elderly patients
NEW YORK — An investigational drug made by Bristol-Myers Squibb works better than aspirin in reducing the risk of complications in certain patients with heart rhythm problems, according to results of a late-stage clinical trial published in the New England Journal of Medicine.
Bristol said results of the phase-3 study comparing apixaban with aspirin showed that in patients with atrial fibrillation who were not suited to take the drug warfarin, apixaban was more effective than aspirin in reducing stroke and systemic embolism.
The investigational drug also was more effective than aspirin in reducing the composite of stroke, systemic embolism, heart attack and vascular death in atrial fibrillation patients.